← Eichor
Study identifier: NCT07009717 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Condition: Chemotherapy-induced Peripheral Neuropathy (CIPN) · Healthy  ·  Sponsor: University of Florida

PhaseN/A
Planned participants30
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersYes

About this study

Great Toe Strength (GTS) is a potential clinical biomarker that has been associated with functional mobility and health; Additionally, GTS has been identified in the literature as one of the early symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this research study is to evaluate GTS in individuals with CIPN and healthy adults using ToeScale and see how it relates to nerve issues from chemotherapy. Additionally, we aim to assess the usability of the novel GTS assessment device, ToeScale among the participants. As a part of this study visit, you will complete some questionnaires followed by GTS and balance and gait assessments.

This description comes directly from the study's public registry record.

Talk to the study team

Hongwu Wang, PhD  ·  +1 (352) 273-9934  ·  hongwu.wang@phhp.ufl.edu

Raghuveer Chandrashekhar, MS  ·  rchandrashekhar@ufl.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of FloridaGainesville, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07009717